SCHEMBL20122876

SCHEMBL20122876

Clc1cc(-c2cccnc2)c2c(c1)c1ccncc1n2CC1CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.45
KCNH2 Q12809 3/20 0.45
DYRK1A Q13627 2/20 0.45
PTGER4 P35408 1/20 0.39
CRHR1 P34998 2/20 0.39
CRHR2 Q13324 1/20 0.39
PRPS1 P60891 1/20 0.39
NFATC1 O95644 1/20 0.38
GSK3B P49841 1/20 0.38
MAT2A P31153 1/20 0.38
EGLN1 Q9GZT9 2/20 0.37
KDM4C Q9H3R0 1/20 0.37
IDO1 P14902 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
RIPK3 Q9Y572 1/20 0.36
AOC3 Q16853 1/20 0.36
METAP2 P50579 1/20 0.35
HPGDS O60760 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664155 1.00 ROCK2 (0.45) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL20122885 0.89 KCNH2 (0.49) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL30664200 0.89 KCNH2 (0.49) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL20122886 0.86 DYRK1A (0.46) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL30664172 0.84 DYRK1A (0.45) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL20123075 0.84 DYRK1A (0.45) ROCK2KCNH2DYRK1APTGER4CRHR1
SCHEMBL30664279 0.84 ROCK2 (0.43) ROCK2KCNH2DYRK1AGSK3BCYP11B1
SCHEMBL20122870 0.84 ROCK2 (0.43) ROCK2KCNH2DYRK1AGSK3BCYP11B1
SCHEMBL20122884 0.84 L3MBTL1 (0.41) ROCK2KCNH2DYRK1ANFATC1GSK3B
SCHEMBL29756304 0.84 L3MBTL1 (0.41) ROCK2KCNH2DYRK1ANFATC1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885KCNH2 3028/4885DYRK1A 493/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 ROCK2 1093/4885KCNH2 3028/4885DYRK1A 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.